background: In assisted reproductive technology, human chorionic gonadotrophin (hCG) is administered subcutaneously for the induction of oocyte maturation and ovulation. Our efforts to develop orally bioavailable luteinizing hormone (LH) receptor agonists have led to the discovery of Org 43553, a low molecular weight (LMW) LH receptor (LH-R) agonist.
Introduction
Luteinizing hormone (LH) is a heterodimeric glycoprotein hormone that plays a pivotal role in ovulation. LH is produced and secreted by the pituitary and binds with high affinity and high specificity to the extra-cellular domain of the LH receptor (LH-R) which belongs to the G protein-coupled receptor (GPCR) superfamily. The LH-R is predominantly expressed in gonadal tissues like ovary and testis and at much lower levels in non-gonadal tissues like oviduct, uterus and blood vessels (Rao, 2001) . At midcycle, the LH surge is responsible for oocyte maturation, cumulus expansion, luteinization and finally follicular rupture in the ovary. Binding of LH to the LH-R also stimulates theca cells (female) and Leydig cells (male) to produce testosterone, which in females can be converted into estradiol by aromatase in granulosa cells.
Human chorionic gonadotrophin (hCG), which is produced during pregnancy to maintain the early stages of pregnancy, also binds to the LH-R (Shoham et al., 1995) . HCG is used in assisted reproductive therapy for oocyte maturation and ovulation induction as well as for luteal support. A disadvantage of urinary as well as recombinant hCG is the heterogeneity of the product and its long half-life (48-96 h in human; Damewood et al., 1989) which significantly exceeds the duration of the LH surge observed in normal cycles (24 -48 h; Hoff et al., 1983; Shoham et al., 1995) . The long half-life of hCG has been associated with a risk for ovarian hyperstimulation syndrome (OHSS) (Itskovitz et al., 1991) . Furthermore, it has been suggested that, due to its long half-life, hCG may interfere with embryo implantation at the endometrium level (Shalev et al., 1995; Licht et al., 1998) .
Another disadvantage in the clinical application of protein hormones like hCG is the required parenteral administration by injection. Therefore, orally bioactive LH-R agonists and FSH-R agonists may revolutionize in vitro fertilization (IVF) treatment (Papanikolaou et al., 2005a) because patient convenience and compliance will improve with oral treatment.
The first report of a bioactive low molecular weight (LMW) gonadotrophin described an FSH-R antagonist (Arey et al., 2002) as a potential compound for female contraception. Others reported small molecule modulators of the FSH receptor (Guo et al., 2004a, b; Van Straten et al., 2005) and LMW compounds (thiazolidinones) with high affinity for the FSH receptor (Maclean et al., 2004; Yanofsky et al., 2006) . In the meantime, other LMW LH-R agonists have been identified (Jorand-Lebrun et al., 2007) , but they displayed in vivo activity only after intraperitoneal administration in the rat. Thus far, no oral bioavailability or oral efficacy has been reported for any of these LMW FSH-R or LH-R modulators. Our search for a LMW, orally bioavailable mimic of LH led to the discovery of the thienopyrimidine compound class (Van Straten et al., 2002) . From an intensive screening program, a number of in vitro-active LMW LH-R agonists were discovered and optimized, eventually leading to Org 43553 (Hanssen and Timmers, 2003) (Figs 1 and 2) . The in vitro signalling pathway of this compound has been already explored (Van Koppen et al., 2008) . The current manuscript describes the pharmacological studies performed with Org 43553 in the period 1999-2003. Subsequently, this compound has been clinically tested and was shown to be effective for ovulation induction at a single dose of 300 mg after oral administration (Mannaerts, 2004) .
We here present extensive in vitro and in vivo pharmacological data for the first orally active agonist of the LH-R (Org 43553).
Materials and Methods

Drugs and reagents
Org 43553 is the hydrogen chloride salt of tert-butyl 5-amino-2-methylthio-4-(3-(2-(morpholin-4-yl)-acetamido)-phenyl)-thieno[2,3-d ]pyrimidine-6-carboxamide and was synthesized by the Department of Medicinal Chemistry at Schering-Plough Research Institute, Oss, The Netherlands.
hCG (Pregnyl w ), used as a reference for LH activity, was of urinary origin. Human recombinant LH was produced at Schering-Plough: cell line CHO-K1.LH.05 was cultivated on microcarriers in a 2 l spinner flask with 1 l serum-containing medium. When the cell population reached 1 Â 10 6 cells/ml, the medium was replaced with a serum-free medium. After 2 -3 days, cell-free culture supernatant was collected and fresh serum-free medium was added to the cells. For 4 weeks, the serumfree medium was replaced every 2 or 3 days. Supernatants from all spinner cultures were pooled for the purification of recombinant LH by a series of chromatographic steps including hydrophobic interaction chromatography, affinity chromatography and size exclusion.
Biotrak enzyme immunoassay kits for cyclic AMP were obtained from Amersham UK. Testosterone and progesterone radioimmunoassays were purchased from ICN Biomedicals Inc., Irvine, USA. All other chemicals were purchased from Sigma-Aldrich, The Netherlands.
Animals
All animal procedures were in accordance with the Dutch animal welfare law and received permission of the Animal Ethical Committee, Organon Oss, The Netherlands.
Immature female mice (B6D2F1/Crl for ovulation induction and B6CBAF1/Crl for follicle culture studies) were obtained from Charles River (Germany).
Mature male Swiss mice for the Leydig cell assay, mature female Wistar rats (used for pharmacokinetic studies) and mature female Orga rats with a regular 4-day estrus cycle were obtained from Hsd/Cpb Harlan (Horst, The Netherlands). All animals were held in our animal facility for at least 1 week prior to the experiments. They were fed a standard diet, were allowed free access to water and were kept in a 14 h light: 10 h darkness schedule (lights on at 6.00 a.m.). 
Ovulation induction by an LMW LH-R agonist
In vitro pharmacological profile
In vitro bioassays for the human LH-R, FSH-R, CRF-R and TSH receptors
The LH-R agonistic activity of Org 43553 was tested in a Chinese hamster ovary (CHO) cell line that stably expresses the human LH-R as well as a cyclic-AMP-response-element (CRE)-inducible luciferase gene. In similar assays, the activity of Org 43553 was tested on two other GPCRs: the human FSH receptor and CRF1 receptor.
The activity of Org 43553 on the human TSH receptor was tested in stably transfected HEK293 cells. Activation of the TSH receptor was determined by measurement of an increased concentration of cAMP, measured by enzyme immunoassay. For all CHO assays, each well of a 96-well white-bottom microtiter plate (Packard) received 50 ml of cells (12 750 cells/well) in DMEM/F12 (Gibco) supplemented with 5% BCS (Hyclone) and without phenol red. Org 43553, suspended in 100% DMSO and diluted in the media (DMSO 1% final concentration), was added to the cells and incubated for 4 h at 378C in humidified atmosphere and containing 95% air, 5% CO 2 . After 4 h, 50 ml of Luclite reagent (Packard) was added per well and the plates were counted in a Topcount scintillation counter (Packard). EC 50 values were calculated with the software GraphPad Prism 3.0.
Ex vivo ovulation induction mouse model
Cultured mouse follicles were used to induce ovulation in vitro as described previously (Rose et al., 1999) . Briefly, ovaries from immature mice (F1: b6BCA; 21 -23 days of age) were removed and placed in Leibovitz-L15 medium (Gibco, Paisley, UK; 11415-049) at 378C. Preantral follicles with a diameter of 170 -200 mm were isolated with two 30-gauge Â 1/2-in. needles attached to 1-ml syringes and collected in aMEM medium (Gibco, 22571 -020) supplemented with glutamine (2 mM), transferrin (10 mg/ml), insulin (5 mg/ml), selenium (2 ng/ml) (aMEM culture medium) and BSA (0.3%). Isolated follicles were incubated in a humidified incubator gassed with 5% CO 2 in air at 378C and individually cultured in Millicell-CM culture plate inserts (Millipore, Bedford, MA, PICM 01 250) with 250 ml aMEM culture medium supplemented with 5% immature mouse serum. Recombinant human FSH (NV Organon, Oss, The Netherlands) 100 mIU/ml (10 ng/ml) was present to induce follicular growth. Culture medium was exchanged every other day. The diameter of the follicles was measured using Â100 magnification and a calibrated micrometer. At the end of the culture period (4 days), follicles which reached the pre-ovulatory stage (.400 mm) were used for ovulation induction. Follicles were induced to ovulate with 0.5, 1 or 5 IU/ml hCG (Pregnyl; NV Organon) or 0.01, 0.1, 1 and 10 mM Org 43553 in aMEM culture medium supplemented with 5% immature mouse serum. After 15 h of incubation, follicles were visually checked for ovulation: follicular rupture, oocyte extrusion and oocyte maturation (as determined by germinal vesicle breakdown). Culture medium was collected 24 h after hCG addition in order to measure progesterone production.
LH activity in primary mouse Leydig cell culture
Leydig cells were isolated from the testis of mature Swiss mice (9 -13 weeks old). The cells were obtained by manual dispersion by drawing the encapsulated testis five times through a glass tube, and after filtration, cells were washed once in M199 culture medium. Of this primary cell suspension (2 ml/testis), 100 ml/well were plated in a 96-well plate and a dose range of Org 43553 or hCG was added (humidified incubator, 378C, 5% CO2). After 4 h of incubation, media were harvested and stored at 2208C until determination of testosterone.
In vitro and in vivo pharmacokinetic profile
Caco-2 transport
Investigation of the transport of Org 43553 across the intestinal wall was performed using human adenocarcinoma colon cells (Caco-2) using the biocoat intestinal epithelium differentiation environment (Biede w ) system. This assay was performed as described previously (Artursson and Karlsson, 1991) . The transport of a compound across the cell monolayer from the apical to the basolateral side was determined by liquid chromatography-mass spectrometry (LC-MS)/MS and quantified as the apparent permeability (Papp, in nm/s). This assay predicts the ability of a compound to become orally bioavailable.
Metabolism in rat and human liver microsomes
A 96-well microtiter plate (flat bottom) was put on a flat bedshaker for incubation at 378C. Then 212.5 ml rat or human liver microsomes (0.588 mg protein/ml) and 12.5 ml NADPH were added to the wells after which the reaction was started by the addition of 25 ml of testosterone (reference) or Org 43553 (stock of 10 mM in phosphate buffer) to the microsomes to give a final concentration of 1 mM. After the addition of the test compound, the plate was immediately mixed, after which 50 ml of the incubation mixture was sampled (T ¼ 0). The remainder of the mixture was incubated for 5, 30 or 60 min at 378C, and after each time interval, 50 ml of the mixture was added to 150 ml acetonitrile in order to stop the reaction. Tests were carried out in duplicate. Concentration of Org 43553 was measured by LC-MS/MS detection.
Pharmacokinetics in female Wistar rats
A pharmacokinetic study with Org 43553 was performed in female cannulated rats. Blood was sampled at regular time intervals during a 24-h period and allowed to clot overnight at 48C to obtain serum after centrifugation (2000 Â g, 15 min). Serum levels of Org 43553 were measured by LC-MS/MS. Pharmacokinetic parameters were calculated after i.v. (5 mg/kg single dose) and oral (50 mg/kg single dose) administration in 10% Cremophore in water. On the basis of serum levels of Org 43553, the following parameters were calculated: area under the curve (AUC), clearance (Cl), elimination half-life (t1 2 ), time (Tmax) and level (Cmax) of maximum concentration and oral bioavailability (program WinNonlin TM , Pharsight, with the non-compartmental model).
Pharmacokinetics in female Beagle dogs
A pharmacokinetic experiment with Org 43553 was also performed in female Beagle dogs after single-dose i.v. (12.5 mg/kg) and p.o. administration (50 mg/kg). Regular blood samples were taken during a 96-h time period. Serum analysis and calculation of pharmacokinetic parameters were as described earlier for female Wistar rats.
In vivo pharmacological profile
Ovulation induction in immature Humegon-primed mice Immature BDF1 mice (20 days of age) were stimulated with Humegon (12.5 IU/mice/s.c.) to initiate follicle growth on day 0 (t ¼ 10.00 h). After 48 h, ovulation was induced with a single dose of Org 43553 (50 mg/kg/p.o. in Cremophore 10% in water) or hCG (500 IU/kg/s.c. in saline; this hCG dose was proven to be efficacious in earlier experiments). The animals were killed by cervical dislocation 72 h after Humegon injection and the oviducts were excised and placed in saline. The number of ova was microscopically assessed by gently pressing the oviducts between two glass plates and counting the oocytes (magnification Â40). This model was used only for rapid screening of new compounds in a fixed dose (50 mg/kg). Active compounds were further profiled in the rat models.
Ovulation induction in cyclic rats
Ovulation induction was also studied in a second pharmacological model using GnRH-antagonist-treated cyclic female Orga rats. For ovulation induction in cyclic rats and fertility after ovulation induction, mature female virgin rats weighing 200 -300 g were used. The cyclic rats were housed in polypropylene type L cages in a light-and temperaturecontrolled room (14 h light -10 h dark, lights on at 6.00 a.m., 21 -238C, 5 -6 animals per cage). Briefly, rats were checked for a regular 4-day estrus cycle for at least two complete cycles. For this, vaginal smears were prepared daily in the morning and evaluated microscopically by determining the percentage of cornified and nucleated epithelial cells and leukocytes. The treatment of the female rats started at pro-estrous phase (nucleated epithelial cells) of the estrus cycle. The rats received a GnRH-antagonist (Org 30850, 10 mg/kg/s.c.) at 1.00 p.m., which results in a 100% blockade of ovulation. At 3.00 p.m., rats were treated with hCG (75 IU/kg/s.c.) or Org 43553 orally in a dose range of 5 -50 mg/kg. The following day, rats were sacrificed and oviducts were excised and the number of ova was microscopically assessed as described earlier.
Implantation and fertility after ovulation induction
The quality of the ovulated ova after ovulation induction by Org 43553 was determined in a fertility test in rats. After treatment for ovulation induction (as described earlier), the female rats were mated with male rats. During the night of pro-estrus, one female rat was housed with one fertile male rat, which were placed in macrolon type III cages with grid bottoms. If on the following day a seminal plug was found in the vagina of the female rat or on the bottom of the cage, mating was regarded successful. The day after mating was considered to be Day 1 of pregnancy. Test compounds were administered as a single dose before mating at 3.00 p.m. (pro-estrus) (Day 0 of pregnancy).
Org 43553 was administered orally in a 10% Cremophore vehicle (1 ml kg 21 ), whereas hCG and rec-LH were administered subcutaneously in a 0.9% NaCl vehicle (1 ml kg 21 ). All compounds (Org 43553, rec-LH and hCG) were tested at a 100% ovulation inducing, dose (25 mg/kg for Org 43553; 400 IU/kg for rec-LH, 150 IU/kg for hCG). At Day 14 of pregnancy, the rats were sacrificed using CO 2 /O 2 gas, uterus and ovaries were dissected free and the number of implanted fetuses in the uterus (alive or in resorption) was counted. In the ovaries, the number of corpora lutea was macroscopically recorded to check whether ovulation had occurred.
Testosterone stimulation in male rats
HCG (1000 IU/kg/s.c.) and Org 43553 (10, 50, 250 mg/kg/p.o.) were administered to adult male rats (n ¼ 3 per treatment group) once daily in the morning, for 7 consecutive days. The highest dose of Org 43553 was 10 times the minimal active dose (MAD) and therefore hCG was also tested at approximately 10 times MAD. Blood samples were obtained from the tail vein at 1 h before administration, at 1, 4 and 8 h on Day 0 and after 1, 2, 4, 6 and 7 days. Blood samples were taken just before the administration of the compounds. For blood collection, rats were placed at elevated ambient temperature in an incubator (408C, 10 min). The rats were weighed and went into autopsy 1 day after the last administration. Testosterone was determined in serum with the Immulite Analyzer of Diagnostics Products Corporation. Samples with levels above the upper detection limit were diluted 1:1 with TRIS buffer and determined again. If still no level could be measured, the highest value of the calibration curve was set as value (111 nmol/l), because of the lack of remaining sample to dilute any further.
Statistical analyses
Data are presented as mean + SEM. All statistical analyses were performed on absolute values. Differences between groups were tested by one-way ANOVA and the multiple range test using Fisher's least significant difference (LSD). Significance was assumed at P , 0.05. The tests were performed using the software STATGRAPHICS Plus for Windows, version 2.1.
Results
In all studies, hCG was only used as reference compound for LH activity and not for dose equivalence comparison.
In vitro pharmacological profile
The EC 50 value for LH-R agonistic activity of Org 43553 in the cellbased LH-R assay was found to be 3.7 Â 10 29 M (the intrinsic receptor activity was 0.8 in this assay, compared with the recombinant human LH standard). In the CHO-FSH receptor assay, Org 43553 showed FSH-R agonistic activity with an EC 50 value of 1.1 Â 10 27 M. No CRF1-R agonistic effect was found using the CHO-CRF1 cell line. Org 43553 was slightly agonistic in the HEK293-TSH receptor assay at concentrations exceeding 3 Â 10 26 M. These in vitro data are summarized in Table I .
To test its ability to induce ovulation of oocytes from isolated follicles, Org 43553 was tested in an ex vivo ovulation induction assay in individually cultured mouse follicles. In this assay, Org 43553 induced the maximal effects of follicular rupture and oocyte maturation (shown as germinal vesicle breakdown) at a concentration of 10 26 M (Table II) . The effects were similar for hCG. A placebo group was not included in this experiment because in many previous experiments, spontaneous follicular rupture was almost never observed (Rose et al., 1999) .
An additional and well-known assay for measuring LH activity is the primary mouse Leydig cell culture. In this assay which uses testosterone as a read out, Org 43553 showed a dose -response curve with an EC 50 value of 6.7 10 28 M (Fig. 3) . Testosterone stimulation by Org 43553 was tested at increasing concentrations from 0.316 nM to 1 mM, and hCG was tested in a range of 0.3 -10 mIU/ml. The maximal effect for Org 43553 was lower than for hCG.
In vitro and in vivo pharmacokinetic profile
Passive intestinal transport was tested in an in vitro model using the Caco-2 cell line. The transport across the cell monolayer from the apical to the basolateral side for Org 43553 showed a high Papp value of 238 nm/s. This implies a very good permeability (internal criteria .100 nm/s) for this compound.
When Org 43553 was incubated with rat liver microsomes, the compound was quickly metabolized, resulting in a half-life of only 5.1 min. Also in the presence of human liver microsomes, the metabolism of Org 43553 was rapid with a half-life of 4.4 min. Because our aim is to administer Org 43553 orally, a high first-pass metabolism may result in a reduced oral bioavailability. In order to assess this, Org 43553 was administered in a single dose intravenously (5 mg/kg) and orally (50 mg/kg) in rats. It was found that Org 43553 has a high oral bioavailability of 79%. The elimination half-life of the compound after intravenous injection was 3.4 h and after oral administration 4.5 h (Table III) . In order to mimic the induction of ovulation by LH-R activation, it is likely that a surge with a high maximum concentration of Org 43553 is required. Indeed, for Org 43553, a very high Cmax (3.8 mg/l) was measured with a rapid decline after oral administration. For allometric scaling, the pharmacokinetic parameters of Org 43553 were also determined in female Beagle dogs (Table III) . Although Org 43553 was also well absorbed in the dog, the oral bioavailability was somewhat lower (44%) ( Table III) .
In vivo pharmacological profile
The first pharmacodynamic in vivo experiment for obtaining proof-of-principle was ovulation induction in immature Humegonprimed mice. A single oral dose of Org 43553 (50 mg/kg) was sufficient to trigger ovulation in 80% of the animals (n ¼ 10), with a mean number of 9.3 ova per ovulating animal. In comparison, the hCG-induced ovulation was more efficacious: 100% of the animals showed a mean number of 58 ova per ovulating animal after subcutaneous administration of 500 IU/kg (Fig. 4) . Subsequently, Org 43553 was tested in a physiologically more relevant cyclic rat ovulation induction model. After single oral administration of Org 43553 in GnRH-antagonist-treated rats, a dose-dependent increase in the number of ovulated oocytes in the ampulla was observed. Already at 5 and 10 mg/kg, ovulation occurred; however, ovulation of a normal number of ova (10-15; similar to the hCG-positive control) was found at a dose of 25 mg/kg. Increasing the dose to 50 mg/kg further increased the number of ovulated ova (Fig. 5) .
The ability of Org 43553 to induce ovulation after oral administration prompted us to evaluate the quality of these oocytes. One of the major actions of LH/hCG is to induce maturation of goodquality oocytes that can successfully be fertilized. Therefore, rats were mated after treatment with Org 43553 (25 mg/kg/p.o.) which induced ovulation. The oocytes displayed a normal fertilization rate, and after fertilization, the resulting embryos showed normal implantation and fetal development, comparable with rec-LH-ovulated oocytes as shown by normal numbers of living embryos (Fig. 6) . In contrast, hCG-ovulated oocytes did not implant in rats, which is in line with literature data (Mattheij et al., 1986; De Boer et al., 1991) . Placebo was not incorporated, as earlier results indicated no spontaneous follicular rupture (Rose et al., 1999 ) (b.d., below detection limit).
Figure 3
The LH-R agonistic activity of increasing concentrations of Org 43553 and hCG in primary mouse Leydig cells. Testosterone production was measured after 4 h of incubation (n ¼ 1, duplicate measurements).
Another in vivo assay to assess the LH activity after oral administration is the stimulation of testosterone production in male rats. During the experiment, the mean basal level of testosterone of the placebo-treated animals was 14.8 + 1.0 nmol/l (range 9.2 -19.5 nmol/l). Oral treatment with Org 43553 resulted in increased testosterone levels. At 10 mg/kg/p.o., a significant increase in testosterone (34 nmol/l) was visible only at 4 h after administration. When Org 43553 was administered at 50 or 250 mg/kg/p.o., testosterone levels were elevated from 1 to 8 h (levels .90 nmol/L). Org 43553 (250 mg/kg/p.o.)-induced testosterone levels were very similar to those induced by hCG and remained above placebo levels during the entire treatment period. Treatment with hCG (1000 IU/kg/s.c.) resulted in a rapid and strong increase of testosterone shown after 1 h. After 24 h, testosterone levels were still high but already declining and the lowest level was reached at 48 h. At all the other time points (96, 144 and 168 h), testosterone levels were elevated and rising again in comparison with placebo ( Fig. 7) .
Discussion
Parenteral administration of hCG has found widespread clinical use in assisted reproductive techniques for oocyte maturation and ovulation induction. LMW LH-R agonists may offer the opportunity to treat patients by using an oral route of delivery. Here we report the in vivo pharmacological characterization of a novel, orally active LMW LH-R agonist, Org 43553.
Org 43553 displays a high potency for the activation of the human LH-R in the nanomolar range and approximately 30 times less affinity for the human FSH receptor. This FSH activity in vitro is too low to stimulate follicle growth in vivo. Org 43553 exhibits no significant activity on the human TSH receptor, which is closely related to the LH and FSH receptor, or on the much more distant CRF-1 receptor. Org 43553 was also shown to evoke an LH response like ovulation-inducing capacity and progesterone synthesis, demonstrated in an ex vivo ovulation model in which isolated mouse follicles were induced to ovulate. However, the concentration needed to induce ovulation was substantially higher in this model compared with the EC 50 values in the in vitro receptor assays. This is probably due to the inclusion of plasma proteins in the medium, which resulted in protein binding of Org 43553. Alternatively, it could be due to lower LH-R expression in the mouse follicles compared with the CHO cell assay, or species differences in LH-R sequence between rat and mouse. In addition, we know that, for ovulation, a high LH surge is necessary. To characterize the in vivo biological LH activity of Org 43553, its ability to induce ovulation in female mice and rats was explored after oral administration. We demonstrate here the first LMW LH-R agonist which is able to induce ovulation after single-dose oral administration. Furthermore, no distinctive abnormalities were noticed: all oocytes were cumulus-enclosed at estrus with normal cumulus expansion and were free from cumulus cells at met-estrus, similar to what is observed in animals treated with either rec-LH or urinary hCG (u-hCG) . In mice, the ovulation rate was somewhat lower than with hCG at the dose level tested. No dose response was tested to reach similar ovulation levels as seen for hCG. In the immature mice model, remarkably higher doses are necessary for adequate ovulation for hCG as well as for Org 43553. The sensitivity of this model seems to be lower than that of the cyclic rat model. Indeed, when a dose-range was tested in the cyclic rat model, the ovulation rate was comparable with hCG at a certain dose. Further, fertilization of Org 43553-ovulated oocytes in the rat model resulted in normal implantation of healthy embryos. Thus our data provide a solid proof-of-concept of in vivo physiological LH-R activation by Org 43553 at the ovarian level (ovulation, oocyte maturation, cumulus expansion). This was subsequently confirmed by the first in human clinical study. In this study, ovulation was shown by transvaginal ultrasound scanning and elevated progesterone levels already at a single dose of 300 mg per subject (Mannaerts, 2004 ). An even more promising LH-R activity on the embryos, compared with hCG, was demonstrated: hCG is known to have a negative maternal effect on embryos in mice and rats (Mattheij et al., 1986; De Boer et al., 1991) , causing strongly reduced implantation numbers. In our hands, these negative implantation effects of hCG were also observed at the dose of 150 IU hCG. Therefore, we decided to test rec-LH as a positive reference compound for LH activity in this fertility model. Interestingly, Org 43553 resembles more rec-LH than hCG with respect to implantation in the rat since we have observed normal numbers of fetuses in rat fertility experiments.
Also in male rats, Org 43553 was active and shown to stimulate testosterone production in an in vitro Leydig cell assay as well as in an in vivo rat model after oral administration.
After the first administration, testosterone levels increased rapidly within hours and declined thereafter almost to basal levels at 48 h for Org 43553 as well as hCG.
It is known that desensitization of LH-R in rat Leydig cells by exogenous hCG occurs slowly and can cause 50 -70% of LH-R loss at 24 h (Dufau et al., 1984) . In contrast, physiological doses of hCG are known to increase the number of LH-Rs at 1 or 2 days after administration, and receptor binding remained sustained for several days (Dufau et al., 1984) . Other in vitro studies with porcine Leydig cells demonstrated that rec-LH produced a rapid desensitization of the receptor-adenylate cyclase system and later an increase of the steroidogenic capacity (Lejeune et al., 1998) . These data can explain the marked drop of testosterone levels at 48 h, whereas sustained testosterone levels were present during the latter treatment period.
Thus, Org 43553 could potentially also be developed for the oral treatment of male hypogonadism to replace subcutaneously administered hCG for this purpose (Finkel et al. 1985) .
For an improved hCG/LH preparation or mimic, besides the improvement of patient convenience by oral treatment, there is also an important additional medical need related to this. OHSS is the most common severe complication of multifollicular ovarian stimulation protocols for IVF/ICSI treatment (Schenker and Weinstein, 1978) and may result in a potentially life-threatening situation (Papanikolaou et al., 2005b) . OHSS is related to the exogenous administration of u-hCG. To induce oocyte maturation, hCG is administered, leading to the production of vasoactive substances like vascular endothelial growth factor (VEGF) by granulosa cells. Human CG has a substantially longer half-life (48-96 h, Damewood et al., 1989; 31-38 h, Saal et al., 1991) than human LH (12 h, le Cotonnec et al., 1998) , thus resulting in massive and sustained follicular luteinization and production of VEGF. This can lead to high vascular permeability and loss of fluid in the abdomen, resulting in OHSS.
Recombinant LH is currently commercially available; however, large dosages are required in women to match the endocrine events typical of inducing ovulation by the endogenous LH surge, and the administration is still parenteral.
To minimize the risk for OHSS, the half-life of Org 43553 should ideally be shorter than for hCG. In vitro, we recorded short half-life times in microsomes, and also in vivo, we found rather short half-lives of 4-5 h, in two species, rat (rodent) and dog (non-rodent).
In contrast, in our experiments in rats, the half-life time for hCG is 14 h after subcutaneous administration, and in dogs it was found to be 32 h after intramuscular administration.
The oral bioavailability of Org 43553 in rat (79%) and dog (44%) was high but showed large species differences. The main difference between dog and rat seemed to be an increased clearance (3.1 l/h) after oral administration for the dog. The Cmax (4.1 mg/l) and half-life (3.5 h) values were comparable with those measured in the rat. Another difference is that, in rat, a continuous bile production will allow Org 43553, which is a lipophylic compound, to be solubilized much easier than in fasted dogs, which were used for the PK study.
On the basis of the pharmacokinetic profile of Org 43553 in rat, the anticipated human half-life of Org 43553 was calculated with a method described by Bachman et al. (1996) . Using this method, the anticipated human half-life of Org 43553 was found to be between 15 and 30 h after a single-dose oral treatment. In a first human exposure study, the human elimination half-life of Org 43553 after oral administration was proven to vary between 30 and 47 h (Mannaerts, 2004) , which is substantially and remarkably shorter than the elimination half-life of hCG (48-96 h in humans). These data suggest that the shorter half-life of Org 43553 in humans compared with hCG may have a reduced risk for OHSS.
Furthermore, Org 43553 is a single, pure synthetic molecule lacking the variability between batches as observed for proteins of urinary or recombinant origin. It is completely protein free, thus totally excluding the minimal current risk for diseases like Creutzfeld Jacob's, originating from recombinant gonadotrophin production in the presence of bovine serum in the culture media.
In summary, the preclinical data presented in this manuscript represent the first report of a LMW compound with a nanomolar potency on the LH-R, showing oral bioavailability and ovulation induction in various animal models. This compound, Org 43553, can be developed as a safe oral alternative to the current injectable LH/hCG preparations for clinical use to induce ovulation or oocyte maturation for both in vivo and IVF therapy. In addition, the compound can also be developed for male indications such as hypogonadism.
